ロード中...
Phase II trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma
BACKGROUND: In vitro studies in mantle cell lymphoma (MCL) cell lines and patient-derived cells have demonstrated synergistic apoptosis with combined rituximab and bortezomib (R-bortezomib), compared to single agent bortezomib. Therefore, we evaluated R-bortezomib in a preclinical model and in a pha...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3116936/ https://ncbi.nlm.nih.gov/pubmed/24048792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25792 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|